<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ENALAPRILAT- enalaprilat injection, solution </strong><br>Hospira, Inc.<br></p></div>
<h1>Enalaprilat Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e9e8ec19-d6b1-4727-a258-7dfe0a210eeb"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">Enalaprilat Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">NOVAPLUS<span class="Sup">®</span>                                                                         </span></span>                                                                    Rx only</p>
<table><tbody class="Headless"><tr class="First Last"><td class="Botrule Lrule Rrule Toprule">
<p class="First"><span class="Bold"><span class="Emphasis">USE IN PREGNANCY</span></span></p>
<span class="Bold"><span class="Emphasis">When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury</span></span> <span class="Bold"><span class="Emphasis">and even <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> to the developing fetus.</span></span> When pregnancy is detected, Enalaprilat Injection, USP should be discontinued as soon as possible. See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS,</a></span> <a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">Fetal/Neonatal Morbidity and Mortality</a></span></span>. </td></tr></tbody></table>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e5ef58a1-38cb-4602-a9b7-a2c68f284048"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Enalaprilat Injection, USP is a sterile aqueous solution for intravenous administration.  Enalaprilat is an angiotensin converting enzyme inhibitor. It is chemically described as (<span class="Italics"><span class="Emphasis">S</span></span>)-1-[<span class="Italics"><span class="Emphasis">N</span></span>-(1-carboxy-3-phenylpropyl)-L-alanyl]-L-proline dihydrate. Its molecular formula is C<span class="Sub">18</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">5</span> • 2H<span class="Sub">2</span>O and its structural formula is:</p>
<p><img alt="enalaprilat-che-str" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3d573a7-50d5-46a8-9f92-baad3ae0831e&amp;name=enalaprilat-injection-usp2-figure-1-enalaprilat-che-str.jpg"></p>
<p>Enalaprilat is a white to off-white, crystalline powder with a molecular weight of 384.43. It is sparingly soluble in methanol and slightly soluble in water.</p>
<p>Each milliliter contains 1.25 mg enalaprilat (anhydrous equivalent); sodium chloride to adjust tonicity; benzyl alcohol, 9 mg, added as a preservative. May contain sodium hydroxide for pH adjustment.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="fba30105-acb4-4215-ad1e-1be1873bf517"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor when administered intravenously, is the active metabolite of the orally administered pro-drug, enalapril maleate. Enalaprilat is poorly absorbed orally.</p>
<p><span class="Bold"><span class="Emphasis">Mechanism of Action</span></span></p>
<p>Intravenous enalaprilat, or oral enalapril, after hydrolysis to enalaprilat, inhibits ACE in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased plasma angiotensin II, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Although the latter decrease is small, it results in small increases of serum potassium. In hypertensive patients treated with enalapril alone for up to 48 weeks, mean increases in serum potassium of approximately 0.2 mEq/L were observed. In patients treated with enalapril plus a thiazide diuretic, there was essentially no change in serum potassium. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a>.</span></span></span>) Removal of angiotensin II negative feedback on renin secretion leads to increased plasma renin activity.</p>
<p>ACE is identical to kininase, an enzyme that degrades bradykinin. Whether increased levels of bradykinin, a potent vasodepressor peptide, play a role in the therapeutic effects of enalaprilat remains to be elucidated.</p>
<p>While the mechanism through which enalaprilat lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system, enalaprilat has antihypertensive activity even in patients with low-renin <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. In clinical studies, black hypertensive patients (usually a low-renin hypertensive population) had a smaller average response to enalaprilat monotherapy than non-black patients.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacokinetics and Metabolism</span></span></p>
<p>Following intravenous administration of a single dose, the serum concentration profile of enalaprilat is polyexponential with a prolonged terminal phase, apparently representing a small fraction of the administered dose that has been bound to ACE. The amount bound does not increase with dose, indicating a saturable site of binding. The effective half-life for accumulation of enalaprilat, as determined from oral administration of multiple doses of enalapril maleate, is approximately 11 hours. Excretion of enalaprilat is primarily renal with more than 90 percent of an administered dose recovered in the urine as unchanged drug within 24 hours. Enalaprilat is poorly absorbed following oral administration.</p>
<p>The disposition of enalaprilat in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is similar to that in patients with normal renal function until the glomerular filtration rate is 30 mL/min or less. With glomerular filtration rate ≤30 mL/min, peak and trough enalaprilat levels increase, time to peak concentration increases and time to steady state may be delayed. The effective half-life of enalaprilat is prolonged at this level of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#a41c8b2a-0f76-4b8f-8fbe-5069ed208666">DOSAGE AND ADMINISTRATION</a></span></span></span>.) Enalaprilat is dialyzable at the rate of 62 mL/min.</p>
<p>Studies in dogs indicate that enalaprilat does not enter the brain, and that enalapril crosses the blood-brain barrier poorly, if at all. Multiple doses of enalapril maleate in rats do not result in accumulation in any tissues. Milk in lactating rats contains radioactivity following administration of <span class="Sup">14</span>C enalapril maleate. Radioactivity was found to cross the placenta following administration of labeled drug to pregnant hamsters.</p>
<p><span class="Bold"><span class="Emphasis">Pharmacodynamics</span></span></p>
<p>Enalaprilat Injection results in the reduction of both supine and standing systolic and diastolic blood pressure, usually with no orthostatic component. Symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span> is therefore infrequent, although it might be anticipated in volume-depleted patients (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>). The onset of action usually occurs within fifteen minutes of administration with the maximum effect occurring within one to four hours. The abrupt withdrawal of enalaprilat has not been associated with a rapid increase in blood pressure.</p>
<p>The duration of hemodynamic effects appears to be dose-related. However, for the recommended dose, the duration of action in most patients is approximately six hours.</p>
<p>Following administration of enalapril, there is an increase in renal blood flow; glomerular filtration rate is usually unchanged. The effects appear to be similar in patients with <span class="product-label-link" type="condition" conceptid="317895" conceptname="Renovascular hypertension">renovascular hypertension</span>.</p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS, Drug Interactions </a></span></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="eca2e291-3355-493c-a4b8-83a203a9344e"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Enalaprilat Injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> when oral therapy is not practical.</p>
<p>Enalaprilat Injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.</p>
<p>In using Enalaprilat Injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> or collagen vascular disease, and that available data are insufficient to show that Enalaprilat Injection does not have a similar risk. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>.)  </p>
<p>In considering use of Enalaprilat Injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> compared to non-blacks. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span></a></span></span></span>.)</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="f3cab6dd-30ff-4bd1-86ff-6277f0725d83"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Enalaprilat Injection is contraindicated in patients who are hypersensitive to any component of this product and in patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="ecb6d8fa-9c27-47d9-b6c5-a0932f23589b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></p>
<p>Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> is rare in uncomplicated hypertensive patients but is a possible consequence of the use of enalaprilat especially in severely salt/volume depleted persons such as those treated vigorously with diuretics or patients on dialysis. Patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, sometimes associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, include those with the following conditions or characteristics: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, high dose diuretic therapy, recent intensive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or increase in diuretic dose, renal dialysis, or severe volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> of any etiology. It may be advisable to eliminate the diuretic, reduce the diuretic dose or increase salt intake cautiously before initiating therapy with Enalaprilat Injection in patients at risk for excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> who are able to tolerate such adjustments. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a></span></span></span>, <span class="Bold"><span class="Emphasis"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">Drug Interactions</a></span></span>, <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#d6723793-7409-4a95-a846-a677a130db31">ADVERSE REACTIONS</a></span></span></span>, and <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#a41c8b2a-0f76-4b8f-8fbe-5069ed208666">DOSAGE AND ADMINISTRATION</a></span></span></span>.) In patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, with or without associated <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> has been observed and may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Because of the potential for an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> especially in these patients, therapy should be followed closely whenever the dose of enalaprilat is adjusted and/or diuretic is increased. Similar considerations may apply to patients with ischemic heart or cerebrovascular disease, in whom an excessive <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> could result in a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>.</p>
<p>If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs, the patient should be placed in the supine position and, if necessary, receive an intravenous infusion of normal saline. A transient hypotensive response is not a contraindication to further doses, which usually can be given without difficulty once the blood pressure has increased after volume expansion.</p>
<p><span class="Bold"><span class="Emphasis">Anaphylactoid and Possibly Related Reactions</span></span></p>
<p>Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides, including endogenous bradykinin, patients receiving ACE inhibitors (including Enalaprilat Injection) may be subject to a variety of adverse reactions, some of them serious.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span></span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors, including enalaprilat. This may occur at any time during treatment. In such cases, Enalaprilat Injection should be promptly discontinued and appropriate therapy and monitoring should be provided until complete and sustained resolution of signs and symptoms has occurred. In instances where <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> may be fatal. <span class="Bold"><span class="Emphasis">Where there is involvement of the tongue, glottis or larynx, likely to cause airway obstruction, appropriate therapy, e.g., subcutaneous epinephrine solution 1:1000 (0.3 mL to 0.5 mL) and/or measures necessary to ensure a patent airway, should be promptly provided. </span></span>(See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#d6723793-7409-4a95-a846-a677a130db31">ADVERSE REACTIONS</a></span></span></span>.)</p>
<p>Patients with a history of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> unrelated to ACE inhibitor therapy may be at increased risk of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> while receiving an ACE inhibitor (see also <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#eca2e291-3355-493c-a4b8-83a203a9344e">INDICATIONS AND USAGE </a></span></span></span>and <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#f3cab6dd-30ff-4bd1-86ff-6277f0725d83">CONTRAINDICATIONS</a></span></span></span>).</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Desensitization:</span></span> Two patients undergoing desensitizing treatment with hymenoptera venom while receiving ACE inhibitors sustained life-threatening <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. In the same patients, these reactions were avoided when ACE inhibitors were temporarily withheld, but they reappeared upon inadvertent rechallenge.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure:</span></span> <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have been reported in patients dialyzed with high-flux membranes and treated concomitantly with an ACE inhibitor. <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> have also been reported in patients undergoing low-density lipoprotein apheresis with dextran sulfate absorption.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span>/<span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span></span></span></p>
<p>Another angiotensin converting enzyme inhibitor, captopril, has been shown to cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>, rarely in uncomplicated patients but more frequently in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> especially if they also have a collagen vascular disease. Available data from clinical trials of enalapril are insufficient to show that enalapril does not cause <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> in similar rates. Marketing experience has revealed cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, or <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> in which a causal relationship to enalapril cannot be excluded. Periodic monitoring of white blood cell counts in patients with collagen vascular disease and <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> should be considered.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></span></span></p>
<p>Rarely, ACE inhibitors have been associated with a syndrome that starts with <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span> and progresses to fulminant <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>, and (sometimes) <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. The mechanism of this syndrome is not understood. Patients receiving ACE inhibitors who develop <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up.</p>
<p><span class="Bold"><span class="Emphasis">Fetal/Neonatal Morbidity and Mortality</span></span></p>
<p>ACE inhibitors can cause fetal and neonatal morbidity and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> when administered to pregnant women. Several dozen cases have been reported in the world literature. When pregnancy is detected, ACE inhibitors should be discontinued as soon as possible.</p>
<p>The use of ACE inhibitors during the second and third trimesters of pregnancy has been associated with fetal and neonatal injury, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, neonatal skull hypoplasia, <span class="product-label-link" type="condition" conceptid="4090272" conceptname="Anuria">anuria</span>, reversible or <span class="product-label-link" type="condition" conceptid="198185" conceptname="Chronic renal failure">irreversible renal failure</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">Oligohydramnios</span> has also been reported, presumably resulting from decreased fetal renal function; <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> in this setting has been associated with fetal limb <span class="product-label-link" type="condition" conceptid="4208264" conceptname="Muscle contracture">contractures</span>, craniofacial deformation, and hypoplastic lung development. <span class="product-label-link" type="condition" conceptid="439128" conceptname="Extreme immaturity">Prematurity</span>, <span class="product-label-link" type="condition" conceptid="80204" conceptname="Fetal growth restriction">intrauterine growth retardation</span>, and <span class="product-label-link" type="condition" conceptid="315922" conceptname="Patent ductus arteriosus">patent ductus arteriosus</span> have also been reported, although it is not clear whether these occurrences were due to the ACE-inhibitor exposure.</p>
<p>These adverse effects do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. Mothers whose embryos and fetuses are exposed to ACE inhibitors only during the first trimester should be so informed. Nonetheless, when patients become pregnant, physicians should make every effort to discontinue the use of Enalaprilat Injection as soon as possible.</p>
<p>Rarely (probably less often than once in every thousand pregnancies), no alternative to ACE inhibitors will be found. In these rare cases, the mothers should be apprised of the potential hazards to their fetuses, and serial ultrasound examinations should be performed to assess the intraamniotic environment.</p>
<p>If <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> is observed, Enalaprilat Injection should be discontinued unless it is considered lifesaving for the mother. Contraction stress testing (CST), a non-stress test (NST), or biophysical profiling (BPP) may be appropriate, depending upon the week of pregnancy. Patients and physicians should be aware, however, that <span class="product-label-link" type="condition" conceptid="434111" conceptname="Oligohydramnios">oligohydramnios</span> may not appear until after the fetus has sustained irreversible injury.</p>
<p>Infants with histories of <span class="Italics"><span class="Emphasis">in utero</span></span> exposure to ACE inhibitors should be closely observed for <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, and <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>. If <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> occurs, attention should be directed toward support of blood pressure and renal perfusion. Exchange transfusion or dialysis may be required as means of reversing <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or substituting for disordered renal function. Enalapril, which crosses the placenta, has been removed from neonatal circulation by peritoneal dialysis with some clinical benefit, and theoretically may be removed by exchange transfusion, although there is no experience with the latter procedure.</p>
<p>No teratogenic effects of oral enalapril were seen in studies of pregnant rats and rabbits. On a body surface area basis, the doses used were 57 times and 12 times, respectively, the maximum recommended human daily dose (MRHDD).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="efcf1ab8-2cfb-4810-815d-311e8e39ed1c"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Bold"><span class="Emphasis">General</span></span></p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4189343" conceptname="Aortic valve stenosis">Aortic Stenosis</span>/<span class="product-label-link" type="condition" conceptid="4124693" conceptname="Hypertrophic cardiomyopathy">Hypertrophic Cardiomyopathy</span></span></span>: As with all vasodilators, enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle.</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span>:</span></span> As a consequence of inhibiting the renin-angiotensin-aldosterone system, changes in renal function may be anticipated in susceptible individuals. In patients with severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> whose renal function may depend on the activity of the renin-angiotensin-aldosterone system, treatment with angiotensin converting enzyme inhibitors, including enalapril or enalaprilat, may be associated with <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span> and/or progressive <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span> and rarely with <span class="product-label-link" type="condition" conceptid="197320" conceptname="Acute renal failure syndrome">acute renal failure</span> and/or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>In clinical studies in hypertensive patients with unilateral or <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">bilateral renal artery stenosis</span>, increases in blood urea nitrogen and serum creatinine were observed in 20 percent of patients receiving enalapril. These increases were almost always reversible upon discontinuation of enalapril or enalaprilat and/or diuretic therapy. In such patients renal function should be monitored during the first few weeks of therapy.</p>
<p>Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when enalaprilat has been given concomitantly with a diuretic. This is more likely to occur in patients with pre-existing <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Dosage reduction of enalaprilat and/or discontinuation of the diuretic may be required.</p>
<p><span class="Bold"><span class="Emphasis">Evaluation of the hypertensive patient should always include assessment of renal function.</span></span> (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#a41c8b2a-0f76-4b8f-8fbe-5069ed208666">DOSAGE AND ADMINISTRATION</a></span></span></span>.)</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span></span></span>: Elevated serum potassium (greater than 5.7 mEq/L) was observed in approximately one percent of hypertensive patients in clinical trials receiving enalapril. In most cases these were isolated values which resolved despite continued therapy. <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> was a cause of discontinuation of therapy in 0.28 percent of hypertensive patients. Risk factors for the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> include <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, and the concomitant use of potassium-sparing agents or potassium supplements, which should be used cautiously, if at all, with Enalaprilat Injection. (See <span class="Bold"><span class="Emphasis"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">Drug Interactions</a></span></span>.)</p>
<p><span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></span></span>: Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> should be considered in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>.</p>
<p><span class="Italics"><span class="Emphasis">Surgery/Anesthesia</span></span>: In patients undergoing major surgery or during anesthesia with agents that produce <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, enalapril may block angiotensin II formation secondary to compensatory renin release. If <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurs and is considered to be due to this mechanism, it can be corrected by volume expansion.</p>
<p><span class="Bold"><span class="Emphasis">Drug Interactions</span></span></p>
<p><span class="Bold"><span class="Emphasis">Gold: </span></span>Nitritoid reactions (symptoms include <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">facial flushing</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy.</p>
<p><span class="Italics"><span class="Emphasis">Hypotension—Patients on Diuretic Therapy</span></span>: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalaprilat. The possibility of hypotensive effects with enalaprilat can be minimized by administration of an intravenous infusion of normal saline, discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalaprilat. If it is necessary to continue the diuretic, provide close medical supervision for at least one hour after the initial dose of enalaprilat. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>.)</p>
<p><span class="Italics"><span class="Emphasis">Agents Causing Renin Release</span></span>: The antihypertensive effect of Enalaprilat Injection appears to be augmented by antihypertensive agents that cause renin release (e.g., diuretics).</p>
<p><span class="Italics"><span class="Emphasis">Non-steroidal Anti-inflammatory Agents</span></span>: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of enalapril may result in a further deterioration of renal function. These effects are usually reversible.</p>
<p>In a clinical pharmacology study, indomethacin or sulindac was administered to hypertensive patients receiving enalapril maleate. In this study there was no evidence of a blunting of the antihypertensive action of enalapril maleate. However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. </p>
<p><span class="Italics"><span class="Emphasis">Other Cardiovascular Agents</span></span>: Enalaprilat Injection has been used concomitantly with digitalis, beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine and prazosin without evidence of clinically significant adverse interactions.</p>
<p><span class="Italics"><span class="Emphasis">Agents Increasing Serum Potassium:</span></span> Enalaprilat Injection attenuates potassium loss caused by thiazide-type diuretics. Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium. Therefore, if concomitant use of these agents is indicated because of demonstrated <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, they should be used with caution and with frequent monitoring of serum potassium.</p>
<p><span class="Italics"><span class="Emphasis">Lithium</span></span>: <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">Lithium toxicity</span> has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors. A few cases of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">lithium toxicity</span> have been reported in patients receiving concomitant enalapril and lithium and were reversible upon discontinuation of both drugs. It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium.</p>
<p><span class="Bold"><span class="Emphasis">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></span></p>
<p>Carcinogenicity studies have not been done with Enalaprilat Injection.</p>
<p>Enalaprilat Injection is the bioactive form of its ethyl ester, enalapril maleate. There was no evidence of a tumorigenic effect when enalapril was administered for 106 weeks to male and female rats at doses up to 90 mg/kg/day or for 94 weeks to male and female mice at doses up to 90 and 180 mg/kg/day, respectively. These doses are 26 times (in rats and female mice) and 13 times (in male mice) the maximum recommended human daily dose (MRHDD) when compared on a body surface area basis. </p>
<p>Enalaprilat Injection was not mutagenic in the Ames microbial mutagen test with or without metabolic activation. Enalapril showed no drug-related changes in the following genotoxicity studies: rec-assay, reverse mutation assay with <span class="Italics"><span class="Emphasis">E. coli</span></span>, sister chromatid exchange with cultured mammalian cells, the micronucleus test with mice, and in an<span class="Italics"><span class="Emphasis"> in vivo</span></span> cytogenic study using mouse bone marrow. There were no adverse effects on reproductive performance of male and female rats treated with up to 90 mg/kg/day of enalapril (26 times the MRHDD when compared on a body surface area basis).</p>
<p><span class="Bold"><span class="Emphasis">Pregnancy</span></span></p>
<p><span class="Italics"><span class="Emphasis">Pregnancy Categories C</span></span> (first trimester) <span class="Italics"><span class="Emphasis">and D</span></span> (second and third trimesters). See <span class="Italics"><span class="Emphasis"><span class="Bold"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS,</a></span> </span></span><span class="Bold"><span class="Emphasis"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">Fetal/Neonatal Morbidity and Mortality.</a></span></span></p>
<p><span class="Bold"><span class="Emphasis">Nursing Mothers</span></span></p>
<p>Enalapril and enalaprilat have been detected in human breast milk. Because of the potential for serious adverse reactions in nursing infants from enalapril, a decision should be made whether to discontinue nursing or to discontinue Enalaprilat Injection, taking into account the importance of the drug to the mother.</p>
<p><span class="Bold"><span class="Emphasis">Pediatric Use </span></span></p>
<p>Safety and effectiveness in pediatric patients have not been established.</p>
<p><span class="Bold"><span class="Emphasis">Geriatric Use</span></span></p>
<p>Clinical studies of Enalaprilat Injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection. Evaluation of the hypertensive patient should always include assessment of renal function. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#a41c8b2a-0f76-4b8f-8fbe-5069ed208666">DOSAGE ANDADMINISTRATION</a></span></span></span>.)</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d6723793-7409-4a95-a846-a677a130db31"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Enalaprilat Injection has been found to be generally well tolerated in controlled clinical trials involving 349 patients (168 with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, 153 with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> and 28 with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>). The most frequent clinically significant adverse experience was <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (3.4 percent), occurring in eight patients (5.2 percent) with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, three (1.8 percent) with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> and one with <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. Other adverse experiences occurring in greater than one percent of patients were: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> (2.9 percent) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1.1 percent).</p>
<p>Adverse experiences occurring in 0.5 to 1.0 percent of patients in controlled clinical trials included: <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>:</span></span> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> has been reported in patients receiving enalaprilat, with an incidence higher in black than in non-black patients. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span> may be fatal. If <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, extremities, lips, tongue, glottis and/or larynx occurs, treatment with enalaprilat should be discontinued and appropriate therapy instituted immediately (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>).</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>:</span></span> See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a></span></span></span>, <span class="Italics"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span>.</span></span></p>
<p><span class="Bold"><span class="Emphasis">Enalapril Maleate</span></span></p>
<p>Since enalapril is converted to enalaprilat, those adverse experiences associated with enalapril might also be expected to occur with Enalaprilat Injection.</p>
<p>The following adverse experiences have been reported with enalapril and, within each category, are listed in order of decreasing severity.</p>
<p><span class="Bold"><span class="Emphasis">Body As A Whole:</span></span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, orthostatic effects, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a>, </span><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span> During Membrane Exposure</a></span></span>), <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>. </p>
<p><span class="Bold"><span class="Emphasis">Cardiovascular:</span></span> <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span>; <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accident</span>, possibly secondary to excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in high risk patients (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a>, </span><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></span></span>); <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> and <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>; <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; rhythm disturbances including <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">atrial tachycardia</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>; <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>; <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>; <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>; <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, Raynaud's phenomenon.</p>
<p><span class="Bold"><span class="Emphasis">Digestive:</span></span> <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (hepatocellular [proven on rechallenge] or <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>) (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a>,</span><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></span></span>), <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">glossitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p><span class="Bold"><span class="Emphasis">Hematologic:</span></span> Rare cases of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span>.</p>
<p><span class="Bold"><span class="Emphasis">Musculoskeletal:</span></span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle cramps</span>.</p>
<p><span class="Bold"><span class="Emphasis">Nervous/Psychiatric:</span></span> <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">peripheral neuropathy</span> (e.g., <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4150134" conceptname="Dysesthesia">dysesthesia</span>), dream abnormality.</p>
<p><span class="Bold"><span class="Emphasis">Respiratory:</span></span> <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span> and <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, pulmonary infiltrates, eosinophilic <span class="product-label-link" type="condition" conceptid="253506" conceptname="Pneumonitis">pneumonitis</span>.</p>
<p><span class="Bold"><span class="Emphasis">Skin:</span></span> <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">Exfoliative dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>, <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">herpes zoster</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>.</p>
<p><span class="Bold"><span class="Emphasis">Special Senses:</span></span> <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste alteration</span>, <span class="product-label-link" type="condition" conceptid="4185711" conceptname="Loss of sense of smell">anosmia</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>, tearing.</p>
<p><span class="Bold"><span class="Emphasis">Urogenital:</span></span> <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>, renal dysfunction (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a></span></span></span> and <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#a41c8b2a-0f76-4b8f-8fbe-5069ed208666">DOSAGE AND ADMINISTRATION</a></span></span></span>), <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="4168447" conceptname="Gynecomastia">gynecomastia</span>, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>.</p>
<p><span class="Bold"><span class="Emphasis">Miscellaneous:</span></span> A symptom complex has been reported which may include some or all of the following: a positive ANA, an elevated <span class="product-label-link" type="condition" conceptid="434481" conceptname="Erythrocyte sedimentation rate - finding">erythrocyte sedimentation rate</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>/<span class="product-label-link" type="condition" conceptid="4291025" conceptname="Arthritis">arthritis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>/<span class="product-label-link" type="condition" conceptid="73001" conceptname="Myositis">myositis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4157025" conceptname="Serositis">serositis</span>, <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and other dermatologic manifestations.</p>
<p><span class="Bold"><span class="Emphasis"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>:</span></span> Combining the results of clinical trials in patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (including <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, and other orthostatic effects) was reported in 2.3 percent of patients following the initial dose of enalapril or during extended therapy. In the hypertensive patients, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> occurred in 0.9 percent and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> occurred in 0.5 percent of patients. <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> was a cause for discontinuation of therapy in 0.1 percent of hypertensive patients. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>.)</p>
<p><span class="Bold"><span class="Emphasis">Fetal/Neonatal Morbidity and Mortality:</span></span> See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a>,</span> <a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">Fetal/Neonatal Morbidity and Mortality</a></span></span>.</p>
<p><span class="Bold"><span class="Emphasis">Clinical Laboratory Test Findings</span></span></p>
<p><span class="Italics"><span class="Emphasis">Serum Electrolytes</span></span>: <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a></span></span></span>), <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>.</p>
<p><span class="Italics"><span class="Emphasis">Creatinine, Blood Urea Nitrogen</span></span>: In controlled clinical trials minor increases in blood urea nitrogen and serum creatinine, reversible upon discontinuation of therapy, were observed in about 0.2 percent of patients with <span class="product-label-link" type="condition" conceptid="320128" conceptname="Essential hypertension">essential hypertension</span> treated with enalapril alone. Increases are more likely to occur in patients receiving concomitant diuretics or in patients with <span class="product-label-link" type="condition" conceptid="4118795" conceptname="Renal artery stenosis">renal artery stenosis</span>. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#efcf1ab8-2cfb-4810-815d-311e8e39ed1c">PRECAUTIONS</a></span></span></span>.)</p>
<p><span class="Italics"><span class="Emphasis">Hematology</span></span>: Small decreases in hemoglobin and hematocrit (mean decreases of approximately 0.3 g percent and 1.0 vol percent, respectively) occur frequently in hypertensive patients treated with enalapril but are rarely of clinical importance unless another cause of <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> co-exists. In clinical trials, less than 0.1 percent of patients discontinued therapy due to <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">Hemolytic anemia</span>, including cases of <span class="product-label-link" type="condition" conceptid="4126829" conceptname="Hemolysis">hemolysis</span> in patients with G-6-PD deficiency, has been reported; a causal relationship to enalapril cannot be excluded.</p>
<p><span class="Italics"><span class="Emphasis">Liver Function Tests</span></span> : Elevations of liver enzymes and/or serum bilirubin have occurred (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a>,</span> <a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Failure</span></a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="cd22c321-87b9-4825-91f4-6a653c78846f"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">In clinical studies, some hypertensive patients received a maximum dose of 80 mg of enalaprilat intravenously over a fifteen minute period. At this high dose, no adverse effects beyond those as associated with the recommended dosages were observed.</p>
<p>A single intravenous dose of ≤4167 mg/kg of enalaprilat was associated with lethality in female mice. No lethality occurred after an intravenous dose of 3472 mg/kg.</p>
<p>The most likely manifestation of overdosage would be <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, for which the usual treatment would be intravenous infusion of normal saline solution.</p>
<p>Enalaprilat may be removed from general circulation by hemodialysis and has been removed from neonatal circulation by peritoneal dialysis. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">,</a></span> <a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">Anaphylactoid ReactionsDuring Membrane Exposure</a></span></span><span class="Bold"><span class="Emphasis">.)</span></span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="a41c8b2a-0f76-4b8f-8fbe-5069ed208666"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">FOR INTRAVENOUS ADMINISTRATION ONLY</p>
<p>The dose in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is 1.25 mg every six hours administered intravenously over a five minute period. A clinical response is usually seen within 15 minutes. Peak effects after the first dose may not occur for up to four hours after dosing. The peak effects of the second and subsequent doses may exceed those of the first.</p>
<p>No dosage regimen for enalaprilat injection has been clearly demonstrated to be more effective in treating <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> than 1.25 mg every six hours. However, in controlled clinical studies in <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, doses as high as 5 mg every six hours were well tolerated for up to 36 hours. There has been inadequate experience with doses greater than 20 mg per day.</p>
<p>In studies of patients with <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, enalaprilat injection has not been administered for periods longer than 48 hours. In other studies, patients have received enalaprilat injection for as long as seven days.</p>
<p>The dose for patients being converted to enalaprilat injection from oral therapy for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> with enalapril maleate is 1.25 mg every six hours. For conversion from intravenous to oral therapy, the recommended initial dose of Enalapril Maleate Tablets is 5 mg once a day with subsequent dosage adjustments as necessary.</p>
<p><span class="Bold"><span class="Emphasis">Patients on Diuretic Therapy</span></span></p>
<p>For patients on diuretic therapy the recommended starting dose for <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> is 0.625 mg administered intravenously over a five minute period; also see below, <span class="Bold"><span class="Emphasis">Patients at Risk of Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span>. A clinical response is usually seen within 15 minutes. Peak effects after the first dose may not occur for up to four hours after dosing, although most of the effect is usually apparent within the first hour. If after one hour there is an inadequate clinical response, the 0.625 mg dose may be repeated. Additional doses of 1.25 mg may be administered at six hour intervals.</p>
<p>For conversion from intravenous to oral therapy, the recommended initial dose of Enalapril Maleate Tablets for patients who have responded to 0.625 mg of enalaprilat every six hours is 2.5 mg once a day with subsequent dosage adjustment as necessary.</p>
<p><span class="Bold"><span class="Emphasis">Dosage Adjustment in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></span></p>
<p>The usual dose of 1.25 mg of enalaprilat every six hours is recommended for patients with a creatinine clearance &gt;30 mL/min (serum creatinine of up to approximately 3 mg/dL). For patients with creatinine clearance ≤30 mL/min (serum creatinine ≥3 mg/dL), the initial dose is 0.625 mg. (See <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>.)</p>
<p>If after one hour there is an inadequate clinical response, the 0.625 mg dose may be repeated. Additional doses of 1.25 mg may be administered at six hour intervals.</p>
<p>For dialysis patients, see below, <span class="Bold"><span class="Emphasis">Patients at Risk of Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span>.</p>
<p>For conversion from intravenous to oral therapy, the recommended initial dose of Enalapril Maleate Tablets is 5 mg once a day for patients with creatinine clearance  &gt;30 mL/min and 2.5 mg once daily for patients with creatinine clearance ≤30 mL/min. Dosage should then be adjusted according to blood pressure response.</p>
<p><span class="Bold"><span class="Emphasis">Patients at Risk of Excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></span></span></p>
<p>Hypertensive patients at risk of excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> include those with the following concurrent conditions or characteristics: <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, high dose diuretic therapy, recent intensive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> or increase in diuretic dose, renal dialysis, or severe volume and/or <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">salt depletion</span> of any etiology (see <span class="Bold"><span class="Emphasis"><span class="Italics"><a href="#ecb6d8fa-9c27-47d9-b6c5-a0932f23589b">WARNINGS</a></span></span></span>). Single doses of enalaprilat as low as 0.2 mg have produced excessive <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> in normotensive patients with these diagnoses. Because of the potential for an extreme hypotensive response in these patients, therapy should be started under very close medical supervision. The starting dose should be no greater than 0.625 mg administered intravenously over a period of no less than five minutes and preferably longer (up to one hour).</p>
<p>Patients should be followed closely whenever the dose of enalaprilat is adjusted and/or diuretic is increased.</p>
<p><span class="Bold"><span class="Emphasis">Administration</span></span></p>
<p>Enalaprilat Injection should be administered as a slow intravenous infusion, as indicated above. It may be administered as provided or diluted with up to 50 mL of a compatible diluent. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to use whenever solution and container permit. </p>
<p><span class="Bold"><span class="Emphasis">Compatibility and Stability</span></span></p>
<p>Enalaprilat Injection as supplied and mixed with the following intravenous diluents has been found to maintain full activity for 24 hours at room temperature:</p>
<p>5 percent Dextrose Injection<br>
    0.9 percent Sodium Chloride Injection<br>
    0.9 percent Sodium Chloride Injection in 5 percent Dextrose<br>
    5 percent Dextrose in Lactated Ringer's Injection <br>
    B. Braun ISOLYTE***E.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ec3f0862-9abc-4b6a-b850-0b004df43aef"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Enalaprilat Injection, USP 1.25 mg per mL, is a clear, colorless solution and is supplied as follows:</p>
<table width=" 513pt"><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Container</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Concentration</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Fill</span></span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold"><span class="Emphasis">Quantity</span></span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0409-2122-13</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg/mL  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 mL  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 per Box</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">0409-2122-88</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Vial</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1.25 mg/mL  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">2 mL  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">1 per Box</p></td>
</tr>
</tbody></table>
<p>Store at 20 to 25°C (68 to 77°F).  [See USP Controlled Room Temperature.] </p>
<p>***Registered trademark of B. Braun</p>
<p>Manufactured by Hospira, Inc., Lake Forest, IL 60045 USA</p>
<p>Novation and NOVAPLUS<span class="Sup">® </span>are trademarks of Novation, LLC.</p>
<p>Revised: March, 2010</p>
<p>Printed in USA                                                     EN-2438</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="f6d180f5-1bab-48ce-8963-723ec9e24911"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">CA-2196</span></span></p>
<p><img alt="NDC-0409-2122-88" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d3d573a7-50d5-46a8-9f92-baad3ae0831e&amp;name=enalaprilat-injection-usp2-figure-2-carton-2196.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ENALAPRILAT 		
					</strong><br><span class="contentTableReg">enalaprilat injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0409-2122</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ENALAPRILAT</strong> (ENALAPRILAT ANHYDROUS) </td>
<td class="formItem">ENALAPRILAT ANHYDROUS</td>
<td class="formItem">1.25 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0409-2122-13</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0409-2122-88</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">2 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075458</td>
<td class="formItem">04/30/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Hospira, Inc.
							(141588017)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>f676ede3-d5c9-4e2f-b601-78b6eac048ca</div>
<div>Set id: d3d573a7-50d5-46a8-9f92-baad3ae0831e</div>
<div>Version: 1</div>
<div>Effective Time: 20140825</div>
</div>
</div> <div class="DistributorName">Hospira, Inc.</div></p>
</body></html>
